Core Insights - NAYA Biosciences is enhancing its focus on oncology and autoimmune diseases by nominating five new board candidates with extensive biotechnology experience [1] Group 1: New Board Members - Laurent Audoly, PhD, cofounder and CEO of PriveBio, has a strong background in R&D and has played a pivotal role in eight drug approvals [2] - Melissa Fensterstock, MPhil, MBA, has experience in translating academic innovations to commercial scale and has held executive positions at prestigious universities [3] - Prakash Raman, PhD, CEO of InduPro, Inc., has significant experience in business development and licensing in the biotechnology sector [4] - Daniel Teper, PharmD, MBA, founder and president of NAYA, has held various senior management positions in leading pharmaceutical companies [5] - Alexandra Urman, MPH, has a background in clinical cancer research and healthcare innovation, currently serving as CEO of Aomics [6] Group 2: Company Overview - NAYA Biosciences is dedicated to developing breakthrough treatments in oncology, autoimmune diseases, and women's health [7] - The company employs a hub & spoke model to optimize the acquisition, development, and partnering of assets, aiming for efficient returns on investment [8] - NAYA's portfolio includes innovative therapies such as NY-303 for hepatocellular carcinoma, NY-338 for multiple myeloma and autoimmune diseases, NY-500 for solid tumors, and NY-600 for metastatic castration-resistant prostate cancer [9]
NAYA Biosciences Announces Nomination of New Board Members